• 1
    Cornoni-Huntley JC,Foley DJ,Guralnik JM. Co-morbidity analysis: a strategy for understanding mortality, disablity and use of health care facilities of older people. Int J Epidemiol. 1991; 20( suppl 1): S8S17.
  • 2
    Piccirillo JF,Tierney RM,Costas I,Grove L,Spitznagel ELJr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004; 291: 24412447.
  • 3
    Yan Y,Carvalhal GF,Catalona WJ,Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000; 88: 11221130.
  • 4
    Alibhai SMH,Krahn MD,Cohen MM,Fleshner NE,Tomlinson G,Naglie G. Is there age bias in the treatment of localized prostate carcinoma? Cancer. 2004; 100: 7281.
  • 5
    Litwin MS,Greenfield S,Elkin EP,Lubeck DP,Broering JM,Kaplan SH. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007; 109: 17771783.
  • 6
    Albertsen PC,Fryback DG,Storer BE,Kolon F,Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol. 1996; 156: 127132.
  • 7
    Newschaffer CJ,Otani K,McDonald MK,Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000; 92: 613621.
  • 8
    Alibhai SM,Leach M,Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst. 2005; 97: 15251532.
  • 9
    Hall WH,Jani AB,Ryu JK,Narayan S,Vijayakumar S. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis. 2005; 8: 2230.
  • 10
    Holowaty EJ,Moravan V,Lee G,Chong N,Dale D. A reabstraction study to estimate the completeness and accuracy of data elements in the Ontario Cancer Registry. Report submitted to Health Canada, February 27, 1996.
  • 11
    Robles SC,Marrett LD,Clarke EA,Risch HA. An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol. 1988; 41: 495501.
  • 12
    Ontario Hospital Association, Ontario Ministry of Health, Hospital Medical Records Institute. Report of the Ontario Data Quality Reabstracting Study. Toronto, Ontario, Canada: Ontario Hospital Association; 1991.
  • 13
    Tu JV,Austin P,Naylor CD,Iron K,Zhang H. Acute myocardial infarction outcomes in Ontario: methods appendix. In: NaylorCD,SlaughterPM, eds. Cardiovascular Health and Services in Ontario: An ICES Atlas. Toronto, Ontario: Institute for Clinical Evaluative Sciences; 1999: 2530.
  • 14
    Charlson ME,Pompei P,Ales KL,MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373383.
  • 15
    Melfi C,Holleman E,Arthur D,Katz B. Selecting a patient characteristics index for the prediction of medical outcomes using administrative claims data. J Clin Epidemiol. 1995; 48: 917926.
  • 16
    Rochon PA,Katz JN,Morrow LA, et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. Med Care. 1996; 34: 10931101.
  • 17
    Greenfield S,Aronow HU,Elashoff RM,Watanabe D. Flaws in mortality data: the hazards of ignoring comorbid disease. JAMA. 1988; 260: 22532255.
  • 18
    Glynn RJ,Monane M,Gurwitz JH,Choodnovskiy I,Avorn J. Aging, comorbidity, and reduced rates of drug treatment for diabetes mellitus. J Clin Epidemiol. 1999; 52: 781790.
  • 19
    Munoz E,Goldstein J,Benacquista T,Mulloy K,Wise L. Diagnosis related group ‘all payor’ hospital payment and medical diseases. Financial risk and hospital cost in medical noncomplicating condition-stratified diagnosis related groups. Arch Intern Med. 1989; 149: 417420.
  • 20
    Satariano WA,Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994; 120: 104110.
  • 21
    Tamblyn R,Lavoie G,Petrella L,Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995; 48: 9991009.
  • 22
    Harrell FEJr,Lee KL,Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361387.
  • 23
    Froehner M,Koch R,Litz R, et al. Preoperative cardiopulmonary risk assessment as predictor of early noncancer and overall mortality after radical prostatectomy. Urology. 2003; 61: 596600.
  • 24
    Agresti A. An Introduction to Categorical Data Analysis. New York, NY: John Wiley & Sons; 1996.
  • 25
    DeLong ER,DeLong DM,Clarke-Pearson DL. Comparing the areas under 2 or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44: 837845.
  • 26
    R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2006.
  • 27
    Bennett CL,Greenfield S,Aronow H,Ganz P,Vogelzang NJ,Elashoff RM. Patterns of care related to age of men with prostate cancer. Cancer. 1991; 67: 26332641.
  • 28
    Desch CE,Penberthy L,Newschaffer CJ, et al. Factors that determine the treatment of local and regional prostate cancer. Med Care. 1996; 34: 152162.
  • 29
    Potosky AL,Merrill RM,Riley GF, et al. Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients. Health Serv Res. 1999; 34: 525546.
  • 30
    Harlan LC,Potosky A,Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001; 93: 18641871.
  • 31
    Eapen L,Villeneuve PJ,Levy IG,Morrison HI. Comorbid survival among elderly male participants of the Canada health survey: relevance to prostate cancer screening and treatment. Chronic Dis Can. 1998; 19: 8490.
  • 32
    Kaplan MH,Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974; 27: 387404.
  • 33
    Froehner M,Koch R,Litz R,Heller A,Oehlschlaeger S,Wirth MP. Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology. 2003; 62: 698701.
  • 34
    Boulos DL,Groome PA,Brundage MD, et al. Predictive validity of 5 comorbidity indices in prostate carcinoma patients treated with curative intent. Cancer. 2006; 106: 18041814.
  • 35
    Linn BS,Linn MW,Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968; 16: 622626.
  • 36
    von Korff M,Wagner EH,Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992; 45: 197203.
  • 37
    Alibhai SMH,Naglie G,Nam R,Trachtenberg J,Krahn MD. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol. 2003; 21: 33183327.
  • 38
    Ghali WA,Hall RE,Rosen AK,Ash AS,Moskowitz MA. Searching for an improved clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol. 1996; 49: 273278.
  • 39
    Elixhauser A,Steiner C,Harris DR,Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998; 36: 827.
  • 40
    Baldwin LM,Klabunde CN,Green P,Barlow W,Wright G. In search of the perfect comorbidity measure for use with administrative claims data: does it exist? Med Care. 2006; 44: 745753.